Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PGC-1α pathway dysregulation disrupts myofiber specification in a mouse model of SBMA
Curtis J. Kuo, Laura B. Chopp, Zhigang Yu, Luhan Ni, Hien T. Zhao, Janghoo Lim, Andrew P. Lieberman
Curtis J. Kuo, Laura B. Chopp, Zhigang Yu, Luhan Ni, Hien T. Zhao, Janghoo Lim, Andrew P. Lieberman
View: Text | PDF
Research Article Muscle biology Neuroscience

PGC-1α pathway dysregulation disrupts myofiber specification in a mouse model of SBMA

  • Text
  • PDF
Abstract

Skeletal muscle pathology is a critical but poorly understood contributor to neuromuscular degeneration in spinal and bulbar muscular atrophy (SBMA), a CAG/polyglutamine (polyQ) expansion disorder caused by mutation in the androgen receptor (AR). Using a gene-targeted SBMA mouse model, we applied single-nucleus RNA sequencing to identify a disease-specific population of skeletal muscle myonuclei that replaced normal myonuclear subtypes. This transition was associated with dysregulation of the pathway governed by PGC-1α, a central regulator of myofiber specification and metabolic identity. PGC-1α dysfunction in SBMA muscle was age, hormone, and polyQ length dependent and was partially rescued by subcutaneous delivery of AR-targeted antisense oligonucleotides. Integrated ChIP-seq and RNA-seq analyses revealed that aberrant PGC-1α activity promoted the expression of a distinct set of myofiber specification genes while downregulating those that define healthy Type IIb and Type IIx myonuclei. We propose a model in which this dysfunction arose downstream of polyQ-mediated sequestration of PGC-1α cofactors MEF2, CREB, and CBP, leading to transcriptional reprogramming and cellular dysfunction. These findings implicated PGC-1α dysregulation as a key event linking AR polyQ expansion to skeletal muscle degeneration and suggested a shared mechanism for polyQ-mediated muscle pathology across related neurodegenerative diseases.

Authors

Curtis J. Kuo, Laura B. Chopp, Zhigang Yu, Luhan Ni, Hien T. Zhao, Janghoo Lim, Andrew P. Lieberman

×

Figure 1

Single-nucleus RNA sequencing reveals a novel, disease-specific population of myonuclei in aged AR113Q mice.

Options: View larger image (or click on image) Download as PowerPoint
Single-nucleus RNA sequencing reveals a novel, disease-specific populati...
(A and B) Representative immunofluorescence images showing staining of Type IIb (A) or Type IIx (B) fibers (magenta) and muscle fiber edges (yellow) in tibialis anterior (TA) from WT (left) and AR113Q (right) male mice at 52 weeks. Right: Quantification of the median cross-sectional area of corresponding muscle fibers (n = 4 mice/group, total fibers measured = 500–2000 per mouse). Scale bars: 100 μm. (C) Unsupervised clustering of nuclei isolated from TA of 3 male WT and 3 male AR113Q mice at 52 weeks, displayed by UMAP. (D) Stacked bar graphs showing relative proportion of the population of each nucleus type across all WT (left) or AR113Q (right) nuclei. (E) Stacked bar graphs showing distribution of nuclei, for each cluster type, between WT (red) and AR113Q (blue) genotype. (F) Number of upregulated, downregulated, and total differentially expressed genes (DEGs) per cluster comparison between WT and AR113Q. For most of the comparisons, DEGs were counted by comparing expression in corresponding clusters, AR113Q vs. WT. However, due to the large discrepancy in number of nuclei in the Type IIb, Type IIb-2, Type IIx, and 113Q-myo clusters, DEGs were counted by pairwise comparisons as indicated. FAPs, fibroadipogenic progenitors; MTJ, myotendinous junction; NOS, not otherwise specified; NMJ, neuromuscular junction. Data are mean ± SD. **P < 0.01, ***P < 0.001 by 2-tailed unpaired t test with Welch’s correction. (A) t = 6.341; df = 3.374; P = 0.0055. (B) t = 7.199, df = 4.837, P = 0.0009.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts